|Dr. Vladimir Coric||CEO & Director||1.14M||N/A||1971|
|Mr. James Engelhart||Chief Financial Officer & Treasurer||656.39k||N/A||1964|
|Ms. Kimberly Gentile||Sr. VP of Clinical Operations||614.09k||1.31M||1966|
|Dr. Elyse Stock M.D.||Chief Medical Officer||594.39k||633.58k||1958|
|Mr. William Jones M.B.A.||Chief Commercial Officer of Migraine & Common Diseases||1.3M||N/A||1964|
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases and rare disorders in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials for acute treatment and prevention of migraine; Vazegepant that has completed Phase 2/3 trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. The company also offers Troriluzole that is in phase II/III clinical stage for obsessive compulsive disorders and Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000, a product that has completed phase I clinical trial for neuropsychiatric disorders; and Verdiperstat, a product that is in phase III trial for multiple system atrophy. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was founded in 2013 and is headquartered in New Haven, Connecticut.
Biohaven Pharmaceutical Holding Company Ltd.’s ISS governance QualityScore as of 8 December 2019 is 10. The pillar scores are Audit: 3; Board: 10; Shareholder rights: 10; Compensation: 9.